Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LB 100

Next Previous
Drug Profile

LB 100

Alternative Names: LB-1; LB-100

Latest Information Update: 06 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lixte Biotechnology Holdings
  • Developer City of Hope National Medical Center; Grupo Espanol de Investigacion en Sarcomas; INSERM; Lixte Biotechnology Holdings; M. D. Anderson Cancer Center; National Cancer Institute (USA)
  • Class Anti-ischaemics; Antidepressants; Antineoplastics; Behavioural disorder therapies; Carboxylic acids; Heterocyclic bicyclo compounds; Piperazines; Small molecules
  • Mechanism of Action Protein phosphatase 2A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I/II Myelodysplastic syndromes; Ovarian cancer; Soft tissue sarcoma
  • Phase I Colorectal cancer
  • Preclinical Behavioural disorders
  • No development reported Angelman syndrome; Ischaemia; Small cell lung cancer; Solid tumours
  • Discontinued Depressive disorders; Haematological disorders

Most Recent Events

  • 06 Sep 2024 LIXTE Biotechnology has patent protection for combining the LB 100 compound with various innovative cancer immunotherapies in USA
  • 18 Jun 2024 Phase-I clinical trials in Colorectal cancer (Metastatic disease, Combination therapy) in Netherlands (IV) (NCT06012734)
  • 17 Jun 2024 Lixte Biotechnology, Roche and Netherlands Cancer Institute (NKI) enters into a research collaboration for a clinical trial for metastatic colon cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top